Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Details)

v3.20.1
Segment Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
segment
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Segment Reporting Information [Line Items]      
Number of Reportable Segments | segment 2    
Net Revenue $ 12,918 $ 6,477  
Other expense (2,540) 16,353  
Segment income (loss) (21,528) (32,608)  
Segment assets 228,759   $ 226,422
Intangible asset, net 7,022   $ 7,377
Dermatology Products Sales [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 11,946 6,125  
Direct cost of goods (3,810) (1,884)  
Sales and marketing costs (4,679) (3,493)  
General and administrative (953) (387)  
Other expense (207)    
Segment income (loss) 2,297 361  
Intangible asset, net 7,022 1,183  
Tangible assets 23,550 9,896  
Total segment assets 30,572 11,079  
Pharmaceutical and Biotechnology Product Development [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 972 352  
Research and development (15,117) (23,723)  
General and administrative (9,887) (9,598)  
Other expense (2,333) 16,353  
Segment income (loss) (26,365) (16,616)  
Tangible assets 198,187 189,459  
Total segment assets 198,187 189,459  
Consolidated [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 12,918 6,477  
Direct cost of goods (3,810) (1,884)  
Sales and marketing costs (4,679) (3,493)  
Research and development (15,117) (23,723)  
General and administrative (10,840) (9,985)  
Other expense (2,540) 16,353  
Segment income (loss) (24,068) (16,255)  
Intangible asset, net 7,022 1,183  
Tangible assets 221,737 199,355  
Total segment assets $ 228,759 $ 200,538